Erasca Announces Merck Collaboration for ERAS-0015, Reports Strong Cash Position and Q1 Results

summarizeSummary

Erasca announced a new clinical collaboration with Merck for its lead asset ERAS-0015, alongside reporting a strong cash position of $408.5 million with an extended runway into H2 2028, and Q1 2026 financial results.

check_boxKey Events

• New Clinical Collaboration with Merck

  Erasca entered a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA® (pembrolizumab). Merck will supply pembrolizumab at no cost, with Erasca as the trial sponsor.

• Strong Cash Position and Runway

  Reported $408.5 million in cash, cash equivalents, and marketable securities as of March 31, 2026, extending its cash runway into the second half of 2028.

• ERAS-4001 Patent Issued

  A U.S. composition of matter patent was issued for ERAS-4001, protecting the pan-KRAS inhibitor until June 2043.

• ERAS-0015 Clinical Advancement Ahead of Schedule

  Monotherapy expansion and combination dose escalation cohorts for ERAS-0015 were initiated ahead of the original second half of 2026 guidance.

auto_awesomeAnalysis

This filing is important due to the new clinical collaboration with Merck, which validates Erasca's lead asset, ERAS-0015, and provides resources for its development. The confirmation of a robust cash position and extended runway into H2 2028 is crucial for a clinical-stage biotech, de-risking its operations. While the net loss increased significantly, it is primarily attributable to a strategic investment in expanding worldwide rights for ERAS-0015, a positive long-term move. The patent for ERAS-4001 further strengthens the company's intellectual property.